Beginning in 2015, Deerfield started the Deerfield Fellows program, designed to attract students with interest in pursuing healthcare or finance fields from local NYC-area colleges and universities from diverse backgrounds for an immersive summer internship program. Successful summer interns are invited to stay through a yearlong Deerfield Fellowship program, with the most successful of those graduating to become Associates at Deerfield. We are extremely proud of the work our Associates do.

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care. As of December 2020, the firm manages more than $13 billion in assets.

Providing value beyond capital, Deerfield generally maintains a combined portfolio of more than 200 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Having many years of operational expertise, Deerfielders are highly engaged and adept at navigating the complex crosscurrents ever-present in the healthcare and financial industries.

Collaboration, intellectual curiosity and pragmatism drive Deerfield’s approach. With its holistic view, Deerfield tailors flexible financing options designed to meet the needs of entrepreneurs and corporate partners.

Meet our team

Deerfield Investment

Supporting companies across the healthcare ecosystem with flexible funding models and value beyond capital.

Search our portfolio

Deerfield Institute

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Institute services

Deerfield Foundation

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Explore our partners

Value beyond capital

Programs

CURE.

At CURE. — Deerfield’s innovation campus on 345 Park Avenue South — we’re transforming healthcare. Here, innovators from across the industry and around the world work shoulder to shoulder to develop treatments to eliminate deadly diseases and create new healthcare delivery models to lower cost and improve care for those in need.

Discover our mission

Established in 2006, the Deerfield Institute delivers sophisticated and timely market research, which enhances the insights available to the investment team and its partners. The Institute develops and analyzes data to advance understanding of innovations and emerging products, and it also informs on trends within the healthcare market. It has published important scientific findings in peer-reviewed journals to extend learnings to the scientific community and benefit public health at large—and  ultimately patients in need. The Institute is guided by Deerfield’s core values: integrity, the pursuit of objective and unbiased research, commitment to excellence, precision and accuracy.

Deerfield Institute Capabilities: 

• Epidemiology
• Scientific Evaluation
• Biostatistics
• Clinical Trial Design, Analysis
• Intellectual Property Evaluation
• Commercial Market Assessment
• Market Access (Pricing, Reimbursement, Access)
• Territory Mapping
• Physician Targeting Plans
• Brand Positioning and Strategic Planning
• Forecasting

PUBLICATIONS

We publish research data to help advance healthcare and to enable researchers to have access to recent, relevant information.

View latest publications

Confidentiality

An affiliate of Deerfield Management, the Deerfield Foundation is a New York City-based not-for-profit devoted to advancing innovative health care initiatives. Since 2007, the Foundation has formed 56 partnerships and invested in the advancement of children’s health, from clinics in the South Bronx to Nepal. Funds are provided through employee contributions and directly from Deerfield’s profits. With these anticipated funds, the Foundation will have resources to fund the development and availability of therapeutics in areas in which philanthropic funding is needed to expand patient treatment options.

Executive Committee

CHAIRMAN: Alexis Cazé

PRESIDENT: Andrew ElBardissi, MD

VICE PRESIDENTS

• David Dalton
• Mike Foley, PhD
• Vicki Gaddy
• Shumaila Irshad
• Emily Tavcar
• Alexandra Truglio

TREASURER: Kerri Seacord

SECRETARY: Kathryn Wilson 

Deerfield Management recognizes that investigators at academic research institutions provide much of the novel insights that advance our understanding of disease. However, at any research institution, the most commercially promising innovations eventually outgrow the lab, requiring greater resources and more focused development expertise than an academic setting can typically provide.

To bridge that gap, Deerfield partners with leading academic research centers from across the country, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Together with its academic partners, Deerfield has created 16 spin-off companies to date that are supporting key avenues from concept to spin-out of novel therapeutic discoveries, as well as an incubator focused on innovative cardiovascular devices.

Deerfield’s 16 academic partnerships, involving 18 institutions, include Boston Children’s Hospital, University of Michigan, Yeda Research and Development Co. Ltd., the commercial arm of the Weizmann Institute of Science; Duke University; Columbia University; Northwestern; Harvard; Vanderbilt; Johns Hopkins; Dana Farber; the Broad Institute; University of North Carolina-Chapel Hill; University of California-San Diego; and the University of Illinois at Chicago. Deerfield also has a combined association with Rockefeller University, Cornell, and Memorial Sloan Kettering Cancer Center through their joint discovery unit, the TDI. Finally, Deerfield has a project-specific collaboration with MD Anderson Cancer Center.

Far beyond its financial resources—with its long vision, operational expertise, and command in the life science and healthcare space for more than two decades, Deerfield is uniquely positioned to support all stages of development from early-stage to market—advancing science and enabling the translation of ideas into medicines.

Researchers at academic institutions discover many of the novel insights that advance our understanding of disease. Commercially promising innovations eventually outgrow the lab, requiring greater resources and more focused development expertise than an academic setting can typically provide. To address this need, Deerfield has pioneered a model of partnership with academic institutions, which creates the potential for rapid funding and advancement of promising therapies. Partner institutions today include: Yeda, the commercial arm of the Weizmann Institute of Science; Duke University; Columbia University; Northwestern; Harvard; Vanderbilt; Johns Hopkins; Dana Farber; the Broad Institute; University of North Carolina-Chapel Hill; University of California-San Diego; and the University of Illinois at Chicago. In addition, Deerfield has a combined association with Rockefeller University, Cornell and Memorial Sloan Kettering Cancer Center through their joint discovery unit, the TDI; and, finally, Deerfield has a project-specific collaboration with MD Anderson Cancer Center.

Deerfield Discovery and Development (3DC) plays a critical role in progressing early-stage therapeutics from scientific discovery through preclinical proof of concept and into the clinic, via design and execution of relevant experiments. 3DC partners closely with principal investigators in Deerfield’s academic collaboration network, corporate partners and entrepreneurs to provide deep functional expertise and experience across key disciplines. These include:

• Genetic Assessment and Insights
• Chemistry
• In Vitro Pharmacology
• Translational Biology
• Drug Metabolism and Pharmacokinetics
• Safety Assessment
• Chemistry, Manufacturing, and Controls (CMC)
• Clinical & Regulatory
• Project Management

Despite the high aptitude of this representative sample of female leaders, the stark reality is boards are only made up of 20% women. Deerfield and Oxeon founded the Break into the Boardroom program (BiB) based on a shared belief that their organizations are uniquely positioned to not only cultivate new female board candidates but to also connect these women with concrete governance opportunities.

Deerfield and Oxeon focus on identifying talent, building companies, and deploying capital within the healthcare ecosystem, which enables BiB to create the perfect intersection of supply and demand. This framework naturally mitigates the classic chicken and egg problem that has proven such an intractable obstacle to the goal of increasing female board representation.

Please visit our website where you may submit inquiries regarding potential board roles or nominate a female executive from your organization to participate in our program.

Deerfield tailors flexible financing options designed to meet the needs of its corporate partners most optimally. Some of our funding options include:

• Growth capital
• Venture Capital
• R&D Financing
• Start-up capital
• Drug discovery and development
• Corporate acquisition
• Product Acquisition
• R&D capital
• Refinancing